Tofacitinib for the Treatment of Pyoderma Gangrenosum

Clin Gastroenterol Hepatol. 2019 Apr;17(5):991-993. doi: 10.1016/j.cgh.2018.10.047. Epub 2018 Nov 4.

Abstract

Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Histocytochemistry
  • Humans
  • Immunohistochemistry
  • Immunologic Factors / administration & dosage*
  • Male
  • Middle Aged
  • Piperidines / administration & dosage*
  • Protein Kinase Inhibitors / administration & dosage*
  • Pyoderma Gangrenosum / drug therapy*
  • Pyoderma Gangrenosum / pathology*
  • Pyrimidines / administration & dosage*
  • Pyrroles / administration & dosage*
  • Skin / pathology
  • Treatment Outcome
  • Young Adult

Substances

  • Immunologic Factors
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • tofacitinib